VitraCell applications

One state-to-fate architecture. Multiple rare-cell problems.

VitraCell focuses on living cells whose future behavior makes them disproportionately important: the tumor cell that survives treatment, the CAR-T cell that persists, the TIL that remains tumor-reactive, or the rare blood-borne cell that must be recovered before it can be studied.

Scope a study Review the research framework

The common problem

The important cell is often identified only after the outcome.

VitraCell's commercial thesis is that preserving identity across time can retain information that is difficult to reconstruct from separate-cell snapshots. The value is application-specific: history must add information that changes a research decision.

Commercial vertical 01 · Oncology

Treatment response, persistence and resistance

Use an identity-preserved longitudinal layer to ask which early cellular states or response patterns distinguish cells that later die, persist, recover or emerge as resistant populations.

Potential sponsor questionsWhich cells become drug-tolerant persisters?Do early response trajectories separate sensitive and resistant fates?Which condition or combination deserves deeper molecular work?

Best initial modelsControlled sensitive/resistant cell-line systemsDefined treatment-survivor modelsLow-input patient-derived models after feasibility is established

Commercial vertical 02 · Cell therapy

Functional heterogeneity in CAR-T, TCR-T, TIL and NK-cell programs

Therapeutic immune cells are living products with heterogeneous function. VitraCell is extending the state-to-fate research model toward questions involving persistence, exhaustion, killing activity, expansion and recovery after defined stimulation or target-cell encounter.

Explore cell-therapy applications →

Potential sponsor questionsWhich starting states precede durable functional persistence?Which cells exhaust or lose cytotoxic function after repeated challenge?Do manufacturing or culture conditions change later cell fate?

Commercial entry pointSponsor-defined feasibility studies using controlled therapeutic-cell modelsEstablished functional endpoints retained as comparatorsResearch-use study design; no lot-release claim implied

Development program · Rare-cell acquisition

CTCs and other scarce viable populations

Vimeran is being developed first for label-free viable CTC recovery from blood. If successful, the acquisition layer can be evaluated for additional rare-cell populations only where cell-specific physics, viability and downstream requirements support it.

Current Vimeran programClinically reasonable blood volumesViability-preserving rare tumor-cell recoveryIdentity retention for downstream characterization

Future expansion criteriaThe cell population is difficult to replace or expand faithfullyViability and identity must be preservedState-to-fate information changes a downstream decision

Commercial discipline

Not every rare cell is a VitraCell market.

Rarity matters only when it creates a meaningful information constraint. VitraCell should pursue applications where the original living cell is difficult to replace, expansion changes the biological question, destructive testing forces a tradeoff, or longitudinal history improves a valuable decision.

Scientific context

Rare pretreatment states and resistanceEmert et al., Nature Biotechnology CAR-T persistenceReview of persistence, exhaustion and efficacy TIL state dynamicsLongitudinal single-cell tracking during melanoma TIL therapy Viable CTC functional studyPantel & Alix-Panabières

Have a rare-cell question with a decision attached?

Send the cell population, perturbation, current endpoint and what your team needs to decide next. VitraCell will determine whether a bounded state-to-fate study is a credible fit.

Scope a study